Metabolic Dysfunction-Associated Steatohepatitis Competitive Landscape and Clinical Trial Analysis Report 2026 Assesses 180+ Companies and 200+ Drugs
Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Competitive Landscape and Clinical Trial Analysis, 2026" has been added to ResearchAndMarkets.com's offering.
The "Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Competitive Landscape and Clinical Trial Analysis, 2026" report delivers a comprehensive global assessment of more than 180 companies and 200 marketed, clinical-stage and preclinical therapies. The report evaluates the MASH drug pipeline by development stage, product type, molecular class and route of administration while also examining inactive and discontinued programs.
Coverage includes company profiles, product assessments, clinical trial designs, development strategies, licensing agreements, collaborations, acquisitions and regulatory milestones. The analysis provides stakeholders with a detailed view of the rapidly evolving MASH treatment landscape and the scientific, clinical and commercial factors shaping future competition.
Global MASH Market and Disease Landscape
Metabolic dysfunction-associated steatohepatitis, formerly known as nonalcoholic steatohepatitis, is the progressive inflammatory form of metabolic dysfunction-associated steatotic liver disease. Its pathology includes hepatic steatosis, hepatocellular injury, lobular inflammation and varying degrees of fibrosis.
MASH pathogenesis involves hepatic lipid accumulation, de novo lipogenesis, impaired lipid oxidation, lipotoxicity, cellular stress, inflammatory signaling and activation of fibrogenic pathways. Interactions among hepatocytes, immune cells, hepatic stellate cells and extrahepatic tissues contribute to disease progression. MASH is strongly associated with obesity, insulin resistance, Type 2 diabetes and dyslipidemia, while fibrosis stage remains a major determinant of long-term clinical outcomes.
The expanding prevalence of metabolic disease continues to drive investment in therapies targeting metabolic, inflammatory and fibrotic mechanisms. Development programs are also incorporating non-invasive assessments to identify patients with clinically significant fibrosis and monitor treatment response.
Major MASH Industry Developments in 2026
Marketed MASH Therapies Covered in the Report
Rezdiffra - Madrigal Pharmaceuticals: Rezdiffra, or resmetirom, is an oral, liver-directed thyroid hormone receptor beta agonist. The FDA approved the therapy in March 2024 for adults with noncirrhotic MASH and moderate-to-advanced fibrosis in combination with diet and exercise. It subsequently received authorization in the European Union and the United Kingdom for eligible adults with F2-F3 fibrosis.
Wegovy - Novo Nordisk: Wegovy, or semaglutide, is a once-weekly GLP-1 receptor agonist. The FDA approved Wegovy in August 2025 for adults with noncirrhotic MASH and F2-F3 fibrosis under the accelerated approval pathway. The decision was supported by histological findings from the ESSENCE clinical trial, with continued approval subject to confirmation of clinical benefit.
Lipaglyn/Bilypsa - Zydus Lifesciences: Saroglitazar magnesium is an oral dual PPAR-alpha/gamma agonist with predominant PPAR-alpha activity. It is approved in India for noncirrhotic MASH and related metabolic liver indications. Its use in MASH remains investigational in the United States.
Selected MASH Pipeline Therapies
Competitive Intelligence and Clinical Trial Analysis
The MASH competitive landscape report compares companies by therapeutic approach, development stage and technology platform. Its commercial assessment examines company-to-company collaborations, industry-academic partnerships, licensing transactions, acquisitions and deal-value trends.
The clinical trial assessment evaluates studies by status, development phase, therapeutic category, participant age, enrollment, completion year and endpoint status. Trial design analysis covers allocation, interventional model, masking and participant status. Sponsor and geographic assessments compare leading trial sponsors, development stages, countries and regional therapy distribution.
The report also addresses company activity, therapeutic classes, active and inactive pipelines, unmet needs and emerging technologies. Key strategic questions include the number of companies developing MASH drugs, the distribution of assets by company and development stage, the status of ongoing clinical studies, recent regulatory designations and the role of mergers, acquisitions, partnerships and licensing agreements in portfolio expansion.
Companies and Products Featured
Prominent companies assessed include Madrigal Pharmaceuticals, Novo Nordisk, Zydus Lifesciences, GSK, Altimmune, D&D Pharmatech, Boehringer Ingelheim, Inventiva Pharma, Galmed Pharmaceuticals, Galectin Therapeutics, Viking Therapeutics, Sagimet Biosciences, Corcept Therapeutics, Can-Fite Biopharma, MediciNova, NorthSea Therapeutics, Rivus Pharmaceuticals, 89bio, Merck, Enanta Pharmaceuticals, Tern Pharmaceuticals and other global developers.
Selected products covered include resmetirom, semaglutide, saroglitazar magnesium, lanifibranor, aramchol, belapectin, VK2809, denifanstat, survodutide, miricorilant, namodenoson, icosabutate, HU6, pegozafermin, efinopegdutide, ARO-HSD, pemvidutide, efimosfermin, zabopegdutide, ALN-CIDEB, IMM-H014 and B1344.
The report provides decision-makers across biopharmaceutical companies, investment organizations, research institutions and healthcare strategy teams with an integrated analysis of the global MASH drug pipeline, clinical trial environment and competitive outlook for 2026 and beyond.
Key Topics Covered:
Introduction
Executive Summary
Metabolic Dysfunction-Associated Steatohepatitis (MASH): Overview
Metabolic Dysfunction-Associated Steatohepatitis (MASH) -Analytical Perspective: In-depth Commercial Assessment
Competitive Landscape
Metabolic Dysfunction-Associated Steatohepatitis (MASH): Company and Product Profiles (Marketed Therapies)
Madrigal Pharmaceuticals
Rezdiffra
Metabolic Dysfunction-Associated Steatohepatitis (MASH): Company and Product Profiles (Pipeline Therapies)
Late Stage Products (Phase III)
GSK
Efimosfermin alfa
Mid Stage Products (Phase II)
D and D Pharmatech
Zabopegdutide
Early Stage Products (Phase I)
Tasly Pharmaceutical Group
B1344
Preclinical Stage Products
Discovery Stage Products
Unknown Stage Products
Therapeutic Assessment
Clinical Trial Assessment
Clinical Trial Analysis
Clinical Trial Design Analysis
Sponsor and Geographical Analysis
Inactive Products
Metabolic Dysfunction-Associated Steatohepatitis (MASH)- Unmet needs
Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Market drivers and barriers
Appendix
List of Tables
Table 1 Total Products for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Assessment by Status
Table 13 Assessment by Status and Phase
Table 14 Assessment by End Point Status
Table 15 Assessment of Enrolled Participants by Age
Table 16 Assessment by Study Completion Year
Table 17 Assessment by Primary Purpose of Clinical Trials
Table 18 Assessment by Allocation of Clinical Trials
Table 19 Assessment by Interventional Model of Clinical Trials
Table 20 Assessment by Masking of Clinical Trials
Table 21 Assessment by Enrolled participants by Status
Table 22 Assessment by Top Sponsors
Table 23 Assessment by Countries and Stage of Development
Table 24 Inactive Products
List of Figures
Figure 1 Total Products for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Assessment by Status
Figure 13 Assessment by Status and Phase
Figure 14 Assessment by End Point Status
Figure 15 Assessment of Enrolled Participants by Age
Figure 16 Assessment by Study Completion Year
Figure 17 Assessment by Primary Purpose of Clinical Trials
Figure 18 Assessment by Allocation of Clinical Trials
Figure 19 Assessment by Interventional Model of Clinical Trials
Figure 20 Assessment by Masking of Clinical Trials
Figure 21 Assessment by Enrolled participants by Status
Figure 22 Assessment by Top Sponsors
Figure 23 Assessment by Countries and Stage of Development
Figure 24 Inactive Products
A selection of companies mentioned in this report includes, but is not limited to:
For more information about this report visit https://www.researchandmarkets.com/r/fhxrir
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.